VP
venBio Partners Portfolio holdings
AUM
$115M
This Quarter Return
+96.42%
1 Year Return
-33.99%
3 Year Return
+221.07%
5 Year Return
+224.54%
10 Year Return
–
AUM
$432M
AUM Growth
+$432M
(+23%)
Cap. Flow
-$77.9M
Cap. Flow
% of AUM
-18.03%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
9
New
–
Increased
–
Reduced
4
Closed
1
Top Buys
No buys this quarter
Top Sells
| 1 |
Akero Therapeutics
AKRO
|
$53.6M |
| 2 |
Harmony Biosciences
HRMY
|
$14.3M |
| 3 |
CINC
CinCor Pharma, Inc. Common Stock
CINC
|
$9.28M |
| 4 |
VRNA
Verona Pharma
VRNA
|
$678K |
| 5 |
Pharvaris
PHVS
|
$36.4K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ventyx Biosciences
VTYX
$171M
| $175M | 40.48% | 5,011,536 | – | – |
|
2
ALX Oncology
ALXO
$62.7M
| $92.8M | 21.48% | 9,699,925 | – | – |
|
|
CINC
3
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
| $61.1M | 14.14% | 1,862,256 -282,779 | -13% | -$9.28M |
|
|
4
Harmony Biosciences
HRMY
$2.12B
| $49.9M | 11.53% | 1,125,673 -323,047 | -22% | -$14.3M |
|
|
5
Akero Therapeutics
AKRO
$3.74B
| $20.3M | 4.7% | 596,483 -1,575,181 | -73% | -$53.6M |
|
|
6
Pharvaris
PHVS
$1.39B
| $17.6M | 4.08% | 2,296,710 -4,741 | -0.2% | -$36.4K |
|
|
IMPL
7
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
| $13.4M | 3.11% | 2,759,791 | – | – |
|
|
ELEV
8
DELISTED
Elevation Oncology
ELEV
| $2.11M | 0.49% | 1,866,339 | – | – |
|
|
VRNA
9
Verona Pharma
VRNA
$9.16B
| – | – | -161,897 | Closed | -$678K |
|